SCHEMBL2904523

SCHEMBL2904523

Cc1c(C(=O)O)sc2cc(C#N)ccc12

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GPR35 Q9HC97 2/20 0.54
▸ RXFP1 Q9HBX9 3/20 0.47
▸ PKM P14618 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ MCL1 Q07820 2/20 0.47
▸ BCL2L1 Q07817 1/20 0.47
▸ TBXAS1 P24557 3/20 0.46
▸ G6PD P11413 1/20 0.43
▸ BCKDK O14874 2/20 0.42
▸ PRNP P04156 1/20 0.41
▸ DYRK1A Q13627 1/20 0.41
▸ ESR1 P03372 1/20 0.39
▸ FNTA P49354 2/20 0.39
▸ FNTB P49356 2/20 0.39
▸ CES2 O00748 1/20 0.39
▸ XDH P47989 2/20 0.38
▸ SLC22A12 Q96S37 2/20 0.38
▸ MIF P14174 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9229662 0.88 GPR35 (0.54) GPR35RXFP1PKMNPSR1MCL1
SCHEMBL15619574 0.79 MCL1 (0.71) GPR35RXFP1PKMNPSR1MCL1
SCHEMBL13730381 0.77 ALDH1A1 (0.39) G6PDDYRK1AMIF
SCHEMBL2895162 0.76 BCKDK (0.67) GPR35RXFP1PKMNPSR1MCL1
SCHEMBL12153769 0.76 MCL1 (0.71) GPR35RXFP1PKMNPSR1MCL1
SCHEMBL2895958 0.76 GPR35 (0.58) GPR35RXFP1PKMNPSR1MCL1
SCHEMBL2896302 0.75 CES2 (0.63) GPR35RXFP1PKMNPSR1MCL1
SCHEMBL29956540 0.74 ENPP2 (0.38) G6PDDYRK1AESR1MIF
SCHEMBL4195351 0.74 ENPP2 (0.38) G6PDDYRK1AESR1MIF
SCHEMBL3572338 0.74 GPR35 (0.55) GPR35RXFP1PKMNPSR1MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7732477-B2 N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-08 — — US disclosed
Send feedback